Regulations and licensing requirements for medical equipment and pharmaceutical sales
First written in FY2016. 23 of 26 entries say "Restated". Latest entry: 2026-05-22.
The whole theme swung hardest in 2026: 4 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Advanced".
- FY2024RestatedAnnual report
「The permit must be renewed every 6 years. In addition, because medical safety is an important issue for the nation, new laws and regulations or permit and licensing systems for medical devices may be introduced in the future.」
The company continues to identify requirements for maintaining and renewing licenses relating to the sale, manufacture and marketing, storage and management of medical devices, pharmaceuticals and other products, as well as the possibility of new regulations being enacted. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2022-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2020RestatedAnnual report
「The permit must be renewed every 6 years. In addition, because medical safety is an important issue for the nation, new laws and regulations or permit and licensing systems for medical devices may be introduced in the future.」
The company continues to identify requirements for maintaining and renewing licenses relating to the sale, manufacture and marketing, storage and management of medical devices, pharmaceuticals and other products, as well as the possibility of new regulations being enacted. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2019RestatedAnnual report
「The permit must be renewed every 6 years. In addition, because medical safety is an important issue for the nation, new laws and regulations or permit and licensing systems for medical devices may be introduced in the future.」
The company continues to identify requirements for maintaining and renewing licenses relating to the sale, manufacture and marketing, storage and management of medical devices, pharmaceuticals and other products, as well as the possibility of new regulations being enacted. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2018RestatedAnnual report
「The permit must be renewed every 5 years. In addition, because medical safety is an important issue for the public and the nation, new laws and regulations or permit and licensing systems for medical devices may be introduced in the future.」
In addition to sales licenses, the company continues to disclose as risks the maintenance of regulations and licenses relating to licenses for the manufacture and marketing of controlled medical devices, expiry dates, biological products, pharmaceuticals, poisons and deleterious substances, nursing-care products and other items. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulatory and licensing risks relating to the sale of medical devices and pharmaceuticals. - FY2017RestatedAnnual report
「The permit must be renewed every 6 years. In addition, because medical safety is an important issue for the nation, new laws and regulations or permit and licensing systems for medical devices may be introduced in the future.」
The company continues to identify as risks the licensing and renewal requirements relating to the sale, manufacture and marketing, storage and management of medical devices, pharmaceuticals and other products, as well as the possibility of new regulations. - FY2017-Q3RestatedAnnual report
「There were no occurrences of matters relating to the business, financial conditions or other items described in this quarterly report that could have a material impact on investors' decisions during the cumulative third quarter, and no significant changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulations and licensing for the sale of medical devices and pharmaceuticals. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding regulations and licensing for the sale of medical devices and pharmaceuticals. - FY2016First statedAnnual report
「As the products handled by the group's companies include highly controlled medical devices, the group has proceeded with establishing responsible personnel and systems in compliance with the requirements of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, and has obtained licenses from the governors of each prefecture for all business locations handling highly controlled medical devices.」
The company is required to maintain permits, registrations and designations relating to medical devices and pharmaceuticals, poisons and deleterious substances, welfare equipment and other products, and permits must be renewed every 6 years.